Posch Alexandra, Hofer-Zeni Sarah, Klieser Eckhard, Primavesi Florian, Naderlinger Elisabeth, Brandstetter Anita, Filipits Martin, Urbas Romana, Swiercynski Stefan, Jäger Tarkan, Winkelmann Paul, Kiesslich Tobias, Lu Lingeng, Neureiter Daniel, Stättner Stefan, Holzmann Klaus
Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
Institute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken (SALK), 5020 Salzburg, Austria.
Cancers (Basel). 2020 Jun 19;12(6):1625. doi: 10.3390/cancers12061625.
Cancer cells activate a telomere maintenance mechanism like telomerase in order to proliferate indefinitely. Telomerase can be reactivated by gain-of-function Telomerase Reverse Transcriptase (TERT) promoter mutations (TPMs) that occur in several cancer subtypes with high incidence and association with diagnosis, prognosis and epigenetics. However, such information about TPMs in sporadic pancreatic neuroendocrine neoplasms (pNENs) including tumor (pNET) and carcinoma (pNEC) is less well defined. We have studied two hot spot TPMs and telomere length (TL) in pNEN and compared the results with clinicopathological information and proliferation-associated miRNA/HDAC expression profiles. DNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissue of 58 sporadic pNEN patients. T allele frequency of C250T and C228T TPM was analyzed by pyrosequencing, relative TL as telomeric content by qPCR. In total, five pNEN cases (9%) including four pNETs and one pNEC were identified with TPMs, four cases with exclusive C250T as predominant TPM and one case with both C250T and C228T. T allele frequencies of DNA isolated from adjacent high tumor cell content FFPE tissue varied considerably, which may indicate TPM tumor heterogeneity. Overall and disease-free survival was not associated with TPM versus wild-type pNEN cases. Binary category analyses indicated a marginally significant relationship between TPM status and longer telomeres ( = 0.086), and changes in expression of miR449a ( = 0.157), HDAC4 ( = 0.146) and HDAC9 ( = 0.149). Future studies with larger patient cohorts are needed to assess the true clinical value of these rare mutations in pNEN.
癌细胞激活一种端粒维持机制,如端粒酶,以便无限增殖。端粒酶可通过功能获得性端粒酶逆转录酶(TERT)启动子突变(TPMs)重新激活,这些突变发生在几种癌症亚型中,发生率高且与诊断、预后和表观遗传学相关。然而,关于散发性胰腺神经内分泌肿瘤(pNENs)包括肿瘤(pNET)和癌(pNEC)中TPMs的此类信息尚不明确。我们研究了pNEN中的两个热点TPMs和端粒长度(TL),并将结果与临床病理信息以及增殖相关的miRNA/HDAC表达谱进行了比较。从58例散发性pNEN患者的福尔马林固定石蜡包埋(FFPE)组织中分离DNA。通过焦磷酸测序分析C250T和C228T TPM的T等位基因频率,通过qPCR分析相对TL作为端粒含量。总共鉴定出5例pNEN病例(9%)存在TPMs,包括4例pNET和1例pNEC,4例以C250T为主要TPM,1例同时存在C250T和C228T。从相邻高肿瘤细胞含量FFPE组织中分离的DNA的T等位基因频率差异很大,这可能表明TPM肿瘤异质性。总体生存和无病生存与TPM与野生型pNEN病例无关。二元分类分析表明TPM状态与较长端粒(P = 0.086)以及miR449a(P = 0.157)、HDAC4(P = 0.146)和HDAC9(P = 0.149)表达变化之间存在微弱的显著关系。需要对更大的患者队列进行进一步研究,以评估这些pNEN中罕见突变的真正临床价值。